Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL539849 | 0.89 | AR (0.35) | ARNR3C1PGRNR3C2CYP1A2 | |
| SCHEMBL830482 | 0.80 | — | — | |
| SCHEMBL840344 | 0.80 | TSHR (0.35) | AR | |
| SCHEMBL1806496 | 0.78 | CES2 (0.31) | — | |
| SCHEMBL16052048 | 0.77 | FFAR4 (0.38) | ARCYP1A2CYP2C9CYP2C19FFAR1 | |
| SCHEMBL29956185 | 0.77 | FFAR4 (0.38) | ARCYP1A2CYP2C9CYP2C19FFAR1 | |
| SCHEMBL6312251 | 0.77 | — | — | |
| SCHEMBL433113 | 0.75 | PLA2G7 (0.34) | ARNR3C1PGR | |
| SCHEMBL16720954 | 0.75 | NR3C1 (0.35) | ARNR3C1PGRNR3C2 | |
| SCHEMBL829740 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133178-B2 | Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer'S disease | PROXIMAGEN LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20130310380-A1 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE | PROXIMAGEN LIMITED (GB) | 2013-11-21 | — | — | US | disclosed |
| EP-2632918-A1 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE | Proximagen Limited (GB) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012055942-A1 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE | PROXIMAGEN LIMITED (GB) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310380-A1 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE | CHRNA7, CHRNA10, CHRNA5 | AR 1758/4885NR3C1 884/4885PGR 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.